Dr Melissa Johnson: Tiragolumab/Atezolizumab Potential New Treatment Option for NSCLC
Prior to this year’s virtual American Society of Clinical Oncology conference held in May, Melissa L. Johnson, MD, associate director for lung cancer research at Sarah Cannon Research Institute and partner in Tennessee Oncology, spoke with The American Journal of Managed Care® on the results of the CITYSCAPE trial, which she presented at the conference. The phase 2 results show that tiragolumab plus atezolizumab may be a chemotherapy-free treatment option for patients with metastatic nonsmall cell lung cancer.
Watch video Dr Melissa Johnson: Tiragolumab/Atezolizumab Potential New Treatment Option for NSCLC online without registration, duration hours minute second in high quality. This video was added by user AJMCtv MJH 09 September 2020, don't forget to share it with your friends and acquaintances, it has been viewed on our site 518 once and liked it 1 people.